CO5210884A1 - DERIVADOS DE 5H-TIAZOLO[3,2-a] PIRIMIDINA - Google Patents

DERIVADOS DE 5H-TIAZOLO[3,2-a] PIRIMIDINA

Info

Publication number
CO5210884A1
CO5210884A1 CO98040510A CO98040510A CO5210884A1 CO 5210884 A1 CO5210884 A1 CO 5210884A1 CO 98040510 A CO98040510 A CO 98040510A CO 98040510 A CO98040510 A CO 98040510A CO 5210884 A1 CO5210884 A1 CO 5210884A1
Authority
CO
Colombia
Prior art keywords
lower alkyl
tiazolo
pyrimidine
derivatives
cycloalkyl
Prior art date
Application number
CO98040510A
Other languages
English (en)
Inventor
Geo Adam
Sabine Folczewski
Vincent Mutel
Jurgen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5210884A1 publication Critical patent/CO5210884A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuesto de la fórmula general<EMI FILE="98040510_1" ID="1" IMF=JPEG >en dondeR1 significa hidrógeno, alquilo inferior, fenilo o bencilo,R2 significa alquilo inferior, alcoxilo inferior,-O(CH2)nN(R13) (R14), -(CH2)nN(R13)(R14) o -N(R15)-(CH2)nN(R13) (R14),R3-R12 significa hidrógeno, halógeno, trifluorometilo, alquilo-inferior,cicloalquilo, alcoxilo inferior, hidroxilo, nitro, ciano, -N(R13)2,fenilo, feniloxilo, bencilo o benciloxilo, oR6 y R7 juntos significan un anillo de benceno,R13-R15 significan hidrógeno, alquilo inferior o cicloalquilo y n significa 1-5,así como sus sales farmacéuticamente aceptables.
CO98040510A 1997-07-18 1998-07-16 DERIVADOS DE 5H-TIAZOLO[3,2-a] PIRIMIDINA CO5210884A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97112324 1997-07-18

Publications (1)

Publication Number Publication Date
CO5210884A1 true CO5210884A1 (es) 2002-10-30

Family

ID=8227080

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98040510A CO5210884A1 (es) 1997-07-18 1998-07-16 DERIVADOS DE 5H-TIAZOLO[3,2-a] PIRIMIDINA

Country Status (33)

Country Link
US (1) US5958931A (es)
EP (1) EP0891978B1 (es)
JP (1) JP3100573B2 (es)
KR (1) KR100296837B1 (es)
CN (1) CN1102596C (es)
AR (1) AR016129A1 (es)
AT (1) ATE214704T1 (es)
AU (1) AU738207B2 (es)
BR (1) BR9802482A (es)
CA (1) CA2243234C (es)
CO (1) CO5210884A1 (es)
CZ (1) CZ288944B6 (es)
DE (1) DE69804273T2 (es)
DK (1) DK0891978T3 (es)
ES (1) ES2172840T3 (es)
HK (1) HK1018439A1 (es)
HR (1) HRP980398B1 (es)
HU (1) HUP9801587A3 (es)
ID (1) ID21824A (es)
IL (1) IL125358A (es)
MA (1) MA26520A1 (es)
NO (1) NO310512B1 (es)
NZ (1) NZ330988A (es)
PE (1) PE97499A1 (es)
PL (1) PL190218B1 (es)
PT (1) PT891978E (es)
RU (1) RU2197493C2 (es)
SI (1) SI0891978T1 (es)
TR (1) TR199801367A2 (es)
TW (1) TW523518B (es)
UY (1) UY25095A1 (es)
YU (1) YU29798A (es)
ZA (1) ZA986250B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074549B1 (en) * 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
CA2672805A1 (en) * 2001-01-31 2002-08-08 H. Lundbeck A/S Pyrimidine derivatives
JPWO2002102807A1 (ja) * 2001-06-14 2004-09-30 萬有製薬株式会社 新規イソキサゾロピリドン誘導体及びその用途
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
MXPA06014809A (es) 2004-06-21 2007-02-12 Hoffmann La Roche Derivados de pirazol-pirimidina.
KR100847160B1 (ko) * 2004-06-21 2008-07-17 에프. 호프만-라 로슈 아게 피라졸로 피리미딘 유도체
CN101115755B (zh) 2005-02-11 2013-01-16 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的吡唑并-嘧啶衍生物
KR100973609B1 (ko) 2005-03-23 2010-08-03 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘유도체
DE602006013493D1 (de) 2005-09-27 2010-05-20 Hoffmann La Roche Oxadiazolylpyrazolopyrimidine als mglur2-antagonisten
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
BRPI0816767B8 (pt) * 2007-09-14 2021-05-25 Addex Pharmaceuticals Sa composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
CN101801930B (zh) * 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
AU2008297876B2 (en) 2007-09-14 2011-07-07 Addex Pharma S.A. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
ES2637794T3 (es) * 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
CN101503414B (zh) * 2009-03-04 2013-10-30 沈阳药科大学 噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102361108B1 (ko) 2013-10-11 2022-02-10 에프. 호프만-라 로슈 아게 N-메틸-d-아스파르테이트 수용체 활성의 조절자로서의 티아졸로피리미딘온
UA121965C2 (uk) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
KR102461134B1 (ko) 2014-01-21 2022-10-28 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
RU2765370C2 (ru) * 2017-03-31 2022-01-28 Басф Се Соединения пиримидиния и их смеси для подавления животных-вредителей

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660418A (en) * 1970-03-16 1972-05-02 Sandoz Ag Certain 2 3 5 6-tetrahydroimidazo(2 1-b)thiazoles
EP0524055A1 (fr) * 1991-07-19 1993-01-20 Synthelabo Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique
PL182285B1 (pl) * 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
GB9609976D0 (en) * 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
AU3783497A (en) * 1996-08-09 1998-03-06 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists

Also Published As

Publication number Publication date
AU738207B2 (en) 2001-09-13
KR100296837B1 (ko) 2001-10-26
CZ288944B6 (cs) 2001-10-17
EP0891978B1 (en) 2002-03-20
TW523518B (en) 2003-03-11
CA2243234A1 (en) 1999-01-18
IL125358A0 (en) 1999-03-12
NZ330988A (en) 1999-03-29
DE69804273T2 (de) 2002-10-31
BR9802482A (pt) 2000-03-14
EP0891978A2 (en) 1999-01-20
HK1018439A1 (en) 1999-12-24
AU7730298A (en) 1999-01-28
ES2172840T3 (es) 2002-10-01
NO983244D0 (no) 1998-07-14
CZ223998A3 (cs) 1999-02-17
PT891978E (pt) 2002-07-31
PL327532A1 (en) 1999-02-01
YU29798A (sh) 2001-12-26
MA26520A1 (fr) 2004-12-20
JP3100573B2 (ja) 2000-10-16
HU9801587D0 (en) 1998-09-28
HRP980398B1 (en) 2002-06-30
ZA986250B (en) 1999-01-22
PE97499A1 (es) 1999-10-12
JPH1171380A (ja) 1999-03-16
PL190218B1 (pl) 2005-11-30
US5958931A (en) 1999-09-28
UY25095A1 (es) 2001-01-31
NO983244L (no) 1999-01-19
IL125358A (en) 2002-09-12
KR19990013919A (ko) 1999-02-25
CA2243234C (en) 2007-09-18
SI0891978T1 (en) 2002-06-30
DK0891978T3 (da) 2002-07-01
ID21824A (id) 1999-07-29
TR199801367A3 (tr) 1999-02-22
CN1102596C (zh) 2003-03-05
NO310512B1 (no) 2001-07-16
ATE214704T1 (de) 2002-04-15
AR016129A1 (es) 2001-06-20
CN1206010A (zh) 1999-01-27
EP0891978A3 (en) 1999-02-03
HUP9801587A2 (hu) 1999-11-29
DE69804273D1 (de) 2002-04-25
HRP980398A2 (en) 1999-04-30
HUP9801587A3 (en) 2001-09-28
RU2197493C2 (ru) 2003-01-27
TR199801367A2 (xx) 1999-02-22

Similar Documents

Publication Publication Date Title
CO5210884A1 (es) DERIVADOS DE 5H-TIAZOLO[3,2-a] PIRIMIDINA
CO5200783A1 (es) Compuestos terapeuticos
CO5180626A1 (es) Derivados de purina inhibidores de proteina quinasa syk
ATE245636T1 (de) Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
CO5070656A1 (es) Analogos de la rapamicina que contienen tetrazol con perio- dos de vida media mas cortos
EA199800170A1 (ru) Производные 2-(4-замещенного)бензиламино-2-метилпропанамида
SE9702773D0 (sv) Novel compounds
ES2188983T3 (es) Nuevas benzofuran-4-carboxamidas.
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
CO5261566A1 (es) Compuestos antipicornavirales y composiciones, sus usos farmaceuticos y materiales para su sintesis
DK1001937T3 (da) Fremgangsmåde til fremstilling af 2-(3-pyrazolyloxymethylen)nitrobenzener
CO5090829A1 (es) Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
RS50229B (sr) Analozi vitamina d3
LU92263I2 (fr) Imépitoïne et ses dérivés pharmaceutiquement acceptables (PEXION)
ES2172029T3 (es) 3-amino-1-cianofenil-uracilos.
ATE219481T1 (de) 1,7,7-trimethyl-bicyclo(2.2.1)heptane derivative
WO2003002580A8 (en) 6-`2-(phosphonomethoxy)alkoxy pyrimidine derivatives having antiviral activity
CO5231155A1 (es) Benzoilciclohexanodionas substituidas
CO5090902A1 (es) Pirroles sustituidos
TR200101808T2 (tr) Psikotik hastalıkların tedavisi için 3-tetrahidropiridin-4-il indoller
CO5210860A1 (es) Nuevos derivados de pirimidina-2,4,6-triona
PA8524001A1 (es) Proceso para preparar 2-(4-piridil)amino-6-dialquiloxifenil-pirido (2,3-d) pirimidin-7-onas
ES2010089A6 (es) Procedimiento para la obtencion de n-oxidos de gamma-carbolina antipsicoticos.
CO5170443A1 (es) Derivados de coclobuten-3,4-diona,su preparacion y su aplicacion terapeutica.

Legal Events

Date Code Title Description
FC Application refused